PepScribe
Category 2 · Educational only

Thymosin Alpha-1: what the research says. | Reddit

More: Clinical standards · Pharmacy partners · Is PepScribe legit?

A 28-amino-acid immune-modulating peptide originally isolated from the thymus gland in 1977. Approved as Zadaxin in 30+ countries with a substantial body of human clinical data. Currently Category 2 in the US, though widely expected to be reclassified.

Regulatory notice: Thymosin Alpha-1 is not an FDA-approved drug and is not currently on FDA’s 503A Bulks List. FDA’s Pharmacy Compounding Advisory Committee reviewed a separate group of peptides for the list on July 23–24, 2026; Thymosin Alpha-1 was not among them.

This page is educational and is not medical advice. Whether any therapy is appropriate is a clinical decision — talk to a PepScribe clinician to discuss your situation and options.

What Thymosin Alpha-1 is.

Thymosin Alpha-1 (Tα1) is a 28-amino-acid peptide originally isolated from the thymus gland, the organ responsible for T-cell maturation and immune system education. It was first characterized by Allan Goldstein at the National Institutes of Health in 1977, making it one of the earliest peptides studied for immune modulation. Enrico Garaci and colleagues at the University of Rome later conducted much of the clinical development work.

Unlike most peptides on the Category 2 list, Thymosin Alpha-1 has a substantial body of human clinical data. It’s marketed as Zadaxin (thymalfasin) and approved as a pharmaceutical product in over 30 countries, including China, India, and across Southeast Asia, for hepatitis B, hepatitis C, and as an immune adjunct in certain cancers. In the US, it’s currently classified as Category 2, but it is widely expected to be reclassified to Category 1 given its established safety record.

How it works.

T-cell maturation

Immune cell development

Research by Goldstein et al. (published across multiple papers in PNAS, 1977–1981) established that Thymosin Alpha-1 promotes maturation and differentiation of T-cells from progenitor cells. T-cells are the immune system’s primary adaptive defense, responsible for identifying and eliminating infected or abnormal cells. This mechanism is well-characterized and forms the basis of its approved uses.

Dendritic cell activation

Antigen presentation

A 2003 study by Romani et al. in Blood demonstrated that Tα1 activates dendritic cells through Toll-like receptor 9 (TLR9) signaling. Dendritic cells act as the immune system’s scouts, they identify threats and present them to T-cells for targeted response. This makes the adaptive immune response more precise.

NK cell enhancement

Natural killer cell activity

Clinical studies by Garaci et al. (1995, International Journal of Immunopharmacology) demonstrated that Tα1 enhances natural killer (NK) cell activity in hepatitis patients, the innate immune cells that provide first-line defense against viral infections and abnormal cell growth.

Immune modulation

Balanced immune response

A 2007 review by Romani et al. in Annals of the New York Academy of Sciences described Tα1’s bidirectional immune effects. Rather than simply stimulating the immune system, Tα1 modulates it, supporting function when underactive and tempering excessive responses. This is why it has been studied in both immune deficiency and autoimmune contexts.

What the research suggests.

Thymosin Alpha-1 has a stronger evidence base than most peptides on this list. Multiple randomized controlled trials in humans have been published, and it has regulatory approval in 30+ countries.

Hepatitis B and C

A 2022 Cochrane systematic review (Zhang et al.) pooled five RCTs covering 353 participants and found Tα1 monotherapy was roughly three-fold superior to placebo for virological response at 12 months after treatment ended; differences at end of treatment and at 6 months post-treatment were not statistically significant. An earlier meta-analysis (Yang et al., Antiviral Research, 2008; four RCTs, 199 patients) compared Tα1 to interferon alpha and reported a similarly delayed benefit pattern, lower response at end of 6-month therapy but higher response 6 months post-treatment. Garaci et al. published supporting RCT data in Hepatology and the International Journal of Immunopharmacology. Tα1 is approved as Zadaxin in multiple countries for hepatitis B; the U.S. FDA has not approved Zadaxin.

Cancer adjunct therapy

A 2010 systematic review by Maio et al. in the Annals of the New York Academy of Sciences analyzed data from over 30 clinical trials using Tα1 as an adjunct to chemotherapy. The review reported improved immune function during treatment, reduced immunosuppression from chemotherapy, and improved response rates when combined with standard protocols in hepatocellular carcinoma and melanoma.

Immune deficiency states

Clinical research by Tuthill et al. (2010, Annals of the New York Academy of Sciences) reviewed Tα1 use in immunocompromised populations, including post-surgical patients, elderly individuals, and those with chronic infections. Data suggests Tα1 may help restore T-cell counts and function. During the COVID-19 pandemic, retrospective studies from Chinese hospitals (Liu et al., 2020, Clinical Infectious Diseases) reported improved outcomes in critically ill patients who received Tα1.

Vaccine enhancement

Garaci et al. (2000, International Immunopharmacology) studied Tα1 as a vaccine adjuvant, improving immune response to influenza vaccination in elderly populations who typically have diminished vaccine responses. The data showed improved seroconversion rates, suggesting a practical application in populations with age-related immune decline.

Administration (research context).

In clinical research and the approved pharmaceutical product Zadaxin, Thymosin Alpha-1 is administered via subcutaneous injection. The established dosing in approved-market formulations is well-documented, typically involving 1.6 mg doses administered subcutaneously two to three times per week over defined treatment periods.

Because Tα1 has approved pharmaceutical formulations in other countries, the dosing and pharmacokinetic data is more robust than for most peptides on the Category 2 list. That said, Tα1 is not currently on FDA’s 503A Bulks List.

This is research context, not prescribing guidance. Thymosin Alpha-1 is handled consultation-first and this information should not be interpreted as a dosing recommendation.

Side effects & safety considerations.

Tα1 has more human safety data than most peptides in this category, drawn from clinical trials and decades of pharmaceutical use abroad.

Common side effects

  • Injection site reactions (redness, swelling, discomfort)
  • Mild flu-like symptoms, this is expected with immune activation and usually resolves within 24–48 hours
  • Temporary fatigue or malaise

Safety profile

Across published clinical trials and decades of pharmaceutical use as Zadaxin, Tα1 has demonstrated a favorable safety profile. A 2010 review by Tuthill et al. in the Annals of the New York Academy of Sciences analyzed safety data from 4,600+ patients across multiple clinical trials and reported serious adverse events in less than 1% of patients. That said, any immune-modulating compound should be used under medical supervision, especially in individuals with autoimmune conditions.

Consult a healthcare provider before considering any peptide therapy. This information is educational and does not replace medical advice.

Legal status.

Thymosin Alpha-1 is not an FDA-approved drug in the United States and is not currently on FDA’s 503A Bulks List. It was not among the peptides FDA’s Pharmacy Compounding Advisory Committee reviewed on July 23–24, 2026.

This is a peptide where the Category 2 classification is widely viewed as an anomaly. Tα1 is approved as Zadaxin in over 30 countries, has extensive human clinical data from thousands of patients, and has been used therapeutically for decades outside the US. It is widely expected to be among the first peptides reclassified to Category 1.

The February 27, 2026 HHS reclassification announcement is expected to include Thymosin Alpha-1, but that announcement carries no legal effect until formally published in the Federal Register.

Deep dives

More on Thymosin Alpha-1.

Research-backed articles covering specific topics in depth.

References

What Reddit says

r/covidlonghaulers235 points328 commentsFeb 2026

5 Years Long Covid - Thymosin Alpha 1 Peptide - WOW!

A five-year long-Covid patient reports 500 mcg of thymosin alpha-1 subcutaneously with near-full symptom relief by day two or three, and the most substantive reply pushes back on the timeframe, attributing the early lift to macrophage activity and warning about tolerance. Three days of self-rated improvement after five years is exactly the pattern that does not hold up without follow-up, which the skeptic asks for; thymosin alpha-1 is an immune modulator, not a stimulant, and is not FDA approved in the US.

Posted on Reddit

Explore clinician-led alternatives.

Thymosin Alpha-1 is not currently on FDA's 503A Bulks List. PepScribe's programs and Tier 1 peptides give a clinician the room to review your goals and the options open to you.

Explore the Longevity programBack to The Peptide Library

Written by B.A. Utterback.

Educational information only. Not medical advice. Treatment decisions are made by a licensed physician.